Albumin modulates the production of matrix metalloproteinases-2 and -9 in podocytes

Abstract

To investigate the effects of albumin on the production of matrix metalloproteinases-2 (MMP-2) and matrix metalloproteinases-9 (MMP-9) in podocytes. Podocytes were treated with bovine serum albumin (BSA) at the concentration of 0.1, 0.5, 1, 2 g/L, respectively. Conditioned media were harvested 12, 24, 48 and 72 h after the treatment. The expression of MMP-2 and MMP-9 was assayed by gelatin zymography, RT-PCR and Western blotting analysis. Our results showed that in comparison with the control group, BSA increased the expression of MMP-2 and MMP-9 mRNA and protein in a dose- and time-dependent manner (P<0.05). Meanwhile, the enzymatic activities of MMP-2 and MMP-9 in the culture supernatants of podocytes were also increased (P<0.05). It is concluded that albumin up-regulated the expression of MMP-2 and MMP-9 at gene and protein levels in a time- and dose-dependent manner.

Keywords

podocytes / albumin / matrix metalloproteinases / glomerular basement membrane

References

[1] MorigiM., BuelliS., AngiolettiS., et al.. In response to protein load podocytes reorganize cytoskeleton and modulate endothelin-1 gene: implication for permselective dysfunction of chronic nephropathies. Am J Pathol, 2005, 166(5): 1309-1320

[2] YoshidaS., NagaseM., ShibataS., et al.. Podocyte injury induced by albumin overload in vivo and in vitro: involvement of TGF-beta and p38 MAPK. Nephron Exp Nephrol, 2008, 108(3): e57-e68

[3] ChenS., LeeJ.S., Iglesias-de la CruzM.C., et al.. Angiotensin II stimulates alpha3 (IV) collagen production in mouse podocytes via TGF-beta and VEGF signalling: Implications for diabetic glomerulopathy. Nephrol Dial Transplant, 2005, 20(7): 1320-1328

[4] LiJ.J., KwakS.J., JungD.S., et al.. Podocyte biology in diabetic nephropathy. Kidney Int (Suppl), 2007, 106: S36-S42

[5] ShanklandS.J., PippinJ.W., ReiserJ., et al.. Podocytes in culture: past, present, and future. Kidney Int, 2007, 72(1): 26-36

[6] JiangH., ZhangC., ZhuZ., et al.. The expression and distribution of CD2 -associated protein in renal cells. Chin J Nephrol (Chinese), 2007, 23(6): 404-405

[7] TakaoT., HorinoT., KagawaT., et al.. Effects of angiotensin II type 1 receptor blocker on albumin-induced cell damage in human renal proximal tubular epithelial cells. Am J Nephrol, 2009, 29(2): 102-108

[8] EyreJ., IoannouK., GrubbB.D., et al.. Statin-sensitive endocytosis of albumin by glomerular podocytes. Am J Physiol Renal Physiol, 2007, 292(2): F674-F681

[9] AbbateM., ZojaC., MorigiM., et al.. Transforming growth factor-beta1 is up-regulated by podocytes in response to excess intraglomerular passage of proteins: a central pathway in progressive glomerulosclerosis. Am J Pathol, 2002, 161(6): 2179-2193

[10] CastroM.M., RizziE., RodriguesG.J., et al.. Antioxidant treatment reduces matrix metalloproteinase-2-induced vascular changes in renovascular hypertension. Free Radic Biol Med, 2009, 46(9): 1298-1307

[11] LuoL., ZhengY.F., DaiY., et al.. Hypercholesterolaemia induces early renal lesions characterized by upregulation of MMP-9 and iNOS and ET(A)R: alleviated by a dual endothelin receptor antagonist CPU0213 and simvastatin. J Pharm Pharmacol, 2009, 61(6): 775-780

[12] EndoT., NakabayashiK., SekiuchiM., et al.. Matrix metalloproteinase-2, matrix metalloproteinase-9, and tissue inhibitor of metalloproteinase-1 in the peripheral blood of patients with various glomerular diseases and their implication in pathogenetic lesions: study based on an enzyme-linked assay and immunohistochemical staining. Clin Exp Nephrol, 2006, 10(4): 253-261

[13] UrushiharaM., KagamiS., KuharaT., et al.. Glomerular distribution and gelatinolytic activity of matrix metalloproteinases in human glomerulonephritis. Nephrol Dial Transplant, 2002, 17(7): 1189-1196

[14] EbiharaI., NakamuraT., ShimadaN., et al.. Increased plasma metalloproteinase-9 concentrations precede development of microalbuminuria in non-insulin-dependent diabetes mellitus. Am J Kidney Dis, 1998, 32(4): 544-550

[15] NakamuraT., UshiyamaC., SuzukiS., et al.. Urinary excretion of podocytes in patients with diabetic nephropathy. Nephrol Dial Transplant, 2000, 15(9): 1379-1383

[16] BaricosW.H., MurphyG., ZhouY.W., et al.. Degradation of glomerular basement membrane by purified mammalian metalloproteinases. Biochem J, 1988, 254(2): 609-612

[17] BaiY., WangL., LiY., et al.. High ambient glucose levels modulates the production of MMP-9 and alpha5 (IV) collagen by cultured podocytes. Cell Physiol Biochem, 2006, 17(1–2): 57-68

[18] KurodaT., YoshidaY., KamiieJ., et al.. Links Expression of MMP-9 in mesangial cells and its changes in anti-GBM glomerulonephritis in WKY rats. Clin Exp Nephrol, 2004, 8(3): 206-215

[19] CosgroveD., MeehanD.T., DelimontD., et al.. Integrin alpha1beta1 regulates matrix metalloproteinases via P38 mitogen-activated protein kinase in mesangial cells: implications for Alport syndrome. Am J Pathol, 2008, 172(3): 761-773

[20] Steinmann-NiggliK., ZiswilerR., KungM., et al.. Inhibition of matrix metalloproteinases attenuates anti-Thy1.1 nephritis. J Am Soc Nephrol, 1998, 9(3): 397-407

[21] CataniaJ.M., ChenG., ParrishA.R.. Role of matrix metalloproteinases in renal pathophysiologies. Am J Physiol Renal Physiol, 2007, 292(3): F905-F911

[22] LelongtB., LegallicierB., PiedagnelR., et al.. Do matrix metalloproteinases MMP-2 and MMP-9 (gelatinases) play a role in renal development, physiology and glomerular diseases?. Curr Opin Nephrol Hypertens, 2001, 10(1): 7-12

[23] FowlkesJ.L., ThrailkillK.M., SerraD.M., et al.. Matrix metalloproteinases as insulin-like growth factor binding protein-degrading proteinases. Prog Growth Factor Res, 1995, 6(2–4): 255-263

[24] ZhongD., SaitoF., SaitoY., et al.. Characterization of the protease activity that cleaves the extracellular domain of beta-dystroglycan. Biochem Biophys Res Commun, 2006, 345(2): 867-871

[25] KretzlerM.. Regulation of adhesive interaction between podocytes and glomerular basement membrane. Microsc Res Tech, 2002, 57(4): 247-253

[26] KojimaK., DavidovitsA., PoczewskiH., et al.. Podocyte flattening and disorder of glomerular basement membrane are associated with splitting of dystroglycan-matrix interaction. J Am Soc Nephrol, 2004, 15(8): 2079-2089

[27] D’AgatiV.D.. Podocyte injury in focal segmental glomerulosclerosis: Lessons from animal models (a play in five acts). Kidney Int, 2008, 73(4): 399-406

[28] ShiS., YuL., ChiuC., et al.. Podocyte-selective deletion of dicer induces proteinuria and glomerulosclerosis. J Am Soc Nephrol, 2008, 19(11): 2159-2169